OncoDNA Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 109

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $7.24M

  • Investors
  • 18

OncoDNA General Information

Description

Operator of a theranostic and genomic company intended to provide precision medicine to treat cancer and genetic diseases. The company provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients and also supports research and drug development in cancer and genetic diseases, helping clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine.

Contact Information

Website
www.oncodna.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rue Louis Breguet 1
  • 6041 Gosselies
  • Belgium
+32 071
Primary Industry
Biotechnology
Other Industries
Decision/Risk Analysis
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Rue Louis Breguet 1
  • 6041 Gosselies
  • Belgium
+32 071

OncoDNA Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoDNA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 05-Jul-2023 $7.24M Completed Generating Revenue
6. Later Stage VC 09-Aug-2021 Completed Generating Revenue
5. Later Stage VC (Series B) 20-Apr-2020 Completed Generating Revenue
4. Later Stage VC 15-Feb-2019 Completed Generating Revenue
3. Early Stage VC (Series A) 01-Sep-2016 Completed Generating Revenue
2. Early Stage VC 15-Dec-2015 $538K $3.1M Completed Generating Revenue
1. Early Stage VC 01-Dec-2012 $2.57M $2.57M Completed Generating Revenue
To view OncoDNA’s complete valuation and funding history, request access »

OncoDNA Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class C
Preferential Shares
Ordinary
Ordinary
Ordinary 240,715 $0.76 $0.76 1x $0.76 1.9%
Ordinary 125,000 $4.35 $4.35 1x $4.35 0.99%
To view OncoDNA’s complete cap table history, request access »

OncoDNA Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a theranostic and genomic company intended to provide precision medicine to treat cancer and genetic disease
Biotechnology
Gosselies, Belgium
109 As of 2024

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoDNA Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Egenesis Venture Capital-Backed Cambridge, MA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
DNAe Venture Capital-Backed London, United Kingdom
QuantuMDx Venture Capital-Backed Newcastle Upon Tyne, United Kingdom
Abionic Venture Capital-Backed Lausanne, Switzerland
You’re viewing 5 of 9 competitors. Get the full list »

OncoDNA Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 14

    Pending

  • Expiring in next 12 mo

OncoDNA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4364752-A1 Improved vaccine Pending 07-Nov-2022
EP-4148146-A1 Method to generate personalized neoantigens of a tumor of a patient Inactive 13-Sep-2021
EP-4147713-A1 A rna vaccine comprising an rna pool generated from a double-stranded dna pool Inactive 13-Sep-2021
EP-4147712-A1 Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient Inactive 13-Sep-2021
CA-3230575-A1 A rna vaccine comprising an rna pool generated from a double-stranded dna pool Pending 13-Sep-2021 C07K14/4748
To view OncoDNA’s complete patent history, request access »

OncoDNA Executive Team (23)

Name Title Board Seat
Bernard Courtieu MD Chief Executive Officer & General Manager
Virginie Decoster Chief Financial Officer
Emmanuel Martin Chief Operating Officer
Gregori Ghitti Chief Data & Innovation Officer
François Degrave Chief Information Officer
You’re viewing 5 of 23 executive team members. Get the full list »

OncoDNA Board Members (19)

Name Representing Role Since
Alain Declercq Self Board Member
An Herremans Ackermans & van Haaren Board Member
Bill Rhodes Self Board Member
Charles-André Brouwers Self Chairman
Francois Fontaine Federal Holding and Investment Company Board Member
You’re viewing 5 of 19 board members. Get the full list »

OncoDNA Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoDNA Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
SFPI Corporation Minority
Wallonie Entreprendre Mezzanine Minority
Federal Holding and Investment Company Holding Company Minority
Swisscanto Private Equity Asset Manager Minority
Verve Ventures Venture Capital Minority
You’re viewing 5 of 18 investors. Get the full list »

OncoDNA Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
IntegraGen 17-Nov-2020 Biotechnology
BioSequence 23-Feb-2017 Merger/Acquisition Biotechnology
To view OncoDNA’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

OncoDNA Subsidiaries (2)

Company Name Industry Location Founded
BioSequence Biotechnology Valencia, Spain 2012
IntegraGen Biotechnology Evry, France
To view OncoDNA’s complete subsidiaries history, request access »

OncoDNA FAQs

  • When was OncoDNA founded?

    OncoDNA was founded in 2012.

  • Who is the founder of OncoDNA?

    Jean-Pol Detiffe, Pierre Lefesvre Ph.D, and François Blondel are the founders of OncoDNA.

  • Who is the CEO of OncoDNA?

    Bernard Courtieu MD is the CEO of OncoDNA.

  • Where is OncoDNA headquartered?

    OncoDNA is headquartered in Gosselies, Belgium.

  • What is the size of OncoDNA?

    OncoDNA has 109 total employees.

  • What industry is OncoDNA in?

    OncoDNA’s primary industry is Biotechnology.

  • Is OncoDNA a private or public company?

    OncoDNA is a Private company.

  • What is the current valuation of OncoDNA?

    The current valuation of OncoDNA is .

  • What is OncoDNA’s current revenue?

    The current revenue for OncoDNA is .

  • How much funding has OncoDNA raised over time?

    OncoDNA has raised $56.7M.

  • Who are OncoDNA’s investors?

    SFPI, Wallonie Entreprendre, Federal Holding and Investment Company, Swisscanto Private Equity, and Verve Ventures are 5 of 18 investors who have invested in OncoDNA.

  • Who are OncoDNA’s competitors?

    Egenesis, Intellia Therapeutics, DNAe, QuantuMDx, and Abionic are some of the 9 competitors of OncoDNA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »